NASH Drugs Market, 2015-2025

The "NASH Drugs Market, 2015-2025" report provides a comprehensive study on the current landscape and the future outlook of the evolving pipeline of molecules in this area. With an expanding NAFLD and NASH population worldwide, there is a growing need for development of therapeutics in this disease area.

Mohali, Punjab, India, September 03, 2015 --( Roots Analysis has announced the addition of “NASH Drugs Market, 2015-2025” report to their offering. The study offers a comprehensive analysis of the current landscape and future outlook of the evolving pipeline of molecules in this area. While the field has garnered interest of several companies, there are no approved therapies till date. It is important to stress that the development pipeline has several promising candidates that are likely to result in many commercial success stories in the foreseen future.

Ishita Nanda, the principal analyst, said, “Amongst other elements, the report elaborates on the new diagnostic solutions being developed and the upcoming opportunities for different stakeholders. As pharmaceutical companies continue to initiate and expand their research programs in this area, one of the key objectives outlined for this report is to understand the future potential of the market. This is done by analyzing:

- The epidemiology, patient population and staging of NASH in different geographies.
- The NASH pipeline in terms of phase of development, type of molecule, route of administration and mechanism of action.
- The likely evolution in the rate of diagnosis, drug treated patient population and the likely price of the drugs.
- The associated constraints, in terms of undefined pathogenesis and the unavailability of non-invasive diagnostic tests, and the initiatives being carried out by companies to overcome these."

Nanda added, “Our opinions and insights were influenced by the discussions that we conducted with experts in this area. These included senior representatives at BiOrion Technologies, Phenex Pharmaceuticals, Tobira Therapeutics, Verlyx Pharmaceuticals and Connexios. Recognizing the huge unmet medical need, several companies are striving to establish an early foothold in the NASH drugs market.”

The 188 page report includes detailed profiles and an assessment of the clinical research pipeline of many companies mentioned below.
- Intercept Pharmaceuticals
- Conatus Pharmaceuticals
- Genfit
- Tobira Therapeutics
- Galmed Pharmaceuticals
- Gilead Sciences
- Galectin Therapeutics
- Islet Sciences
- Raptor Pharmaceuticals
- Zydus Cadila

Several other companies (mostly start-ups), which have molecules in early stages of development, have also been covered. Examples of such companies include Cerenis Therapeutics, DS Biopharma, Immuron, Matinas BioPharma, Metabolic Solutions, Naia Pharmaceuticals, Nimbus Therapeutics, Verva Pharmaceuticals, ViroBay and Zafgen. This study is targeted towards research groups working in the field of liver disorders.

For additional details, please visit

or email
Roots Analysis
Gaurav Chaudhary